| Gene symbol | PPP1R1A | Synonyms | I1, IPP1 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12q13.2 | dbXrefs | |
| Description | protein phosphatase 1 regulatory inhibitor subunit 1A | ||||
| GTO ID | GTC3219 |
| Trial ID | NCT05598333 |
| Disease | Congestive Heart Failure | Non-Ischemic Cardiomyopathy |
| Altered gene | PPP1R1A |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | AB-1002|NAN-101 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy |
| Year | 2022 |
| Country | United States |
| Company sponsor | Asklepios Biopharmaceutical, Inc. |
| Other ID(s) | ASK-CHF2-CS201 |
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||